RobertMBermanMD

Physician

Dr. Berman is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Office
Milstein 9 Garden North
177 Fort Washington Avenue
New York, NY 10032
Phone+1 212-305-3090

Fax+1 212-305-4724

New York Presbyterian Hospital (Cornell Campus)Residency, Psychiatry, 2000 - 2004
University of Pittsburgh School of MedicineClass of 2000

PubMed

8 citations
Assessing Effects of BHV-0223 40 mg Zydis Sublingual Formulation and Riluzole 50 mg Oral Tablet on Liver Function Test Parameters Utilizing DILIsym.
Diane M. Longo, Lisl K.M. Shoda, Brett A. Howell, Vladimir Coric, Robert M. Berman
Toxicological Sciences. 2020-06-01
6 citations
A Pharmacokinetic Bioequivalence Study Comparing Sublingual Riluzole (BHV-0223) and Oral Tablet Formulation of Riluzole in Healthy Volunteers.
Irfan Qureshi, Meghan Lovegren, Victoria Wirtz, Richard Larouche, Mario Tanguay
Clinical Pharmacology in Drug Development. 2020-05-01
33 citations
The γ-Secretase Modulator, BMS-932481, Modulates Aβ Peptides in the Plasma and Cerebrospinal Fluid of Healthy Volunteers.
Holly Soares, Maciej Gasior, Jeremy H. Toyn, Jun-Sheng Wang, Quan Hong
The Journal of Pharmacology and Experimental Therapeutics. 2016-01-01

Positive 3-Year VenoValve(R) First-in-Human Data Presented at 49th Annual VEITH Symposium on Vascular and Endovascular IssuesNovember 17th, 2022
Envveno Medical Reports Successful Completion of First VenoValve Surgery for US Pivotal TrialOctober 26th, 2021
Fast-Acting Depression Drug, Newly Approved, Could Help MillionsMarch 6th, 2019